These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


215 related items for PubMed ID: 1358662

  • 1. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography.
    Seeman P, Guan HC, Civelli O, Van Tol HH, Sunahara RK, Niznik HB.
    Eur J Pharmacol; 1992 Oct 01; 227(2):139-46. PubMed ID: 1358662
    [Abstract] [Full Text] [Related]

  • 2. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
    Malmberg A, Jerning E, Mohell N.
    Eur J Pharmacol; 1996 May 06; 303(1-2):123-8. PubMed ID: 8804920
    [Abstract] [Full Text] [Related]

  • 3. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
    Seeman P, Tallerico T, Ko F.
    Synapse; 2003 Sep 15; 49(4):209-15. PubMed ID: 12827639
    [Abstract] [Full Text] [Related]

  • 4. Distinct binding patterns of [3H]raclopride and [3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for pet studies.
    Bischoff S, Gunst F.
    J Recept Signal Transduct Res; 1997 Sep 15; 17(1-3):419-31. PubMed ID: 9029505
    [Abstract] [Full Text] [Related]

  • 5. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
    Niznik HB, Grigoriadis DE, Pri-Bar I, Buchman O, Seeman P.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun 15; 329(4):333-43. PubMed ID: 2863760
    [Abstract] [Full Text] [Related]

  • 6. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
    Seeman P, Tallerico T.
    Am J Psychiatry; 1999 Jun 15; 156(6):876-84. PubMed ID: 10360126
    [Abstract] [Full Text] [Related]

  • 7. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P, Guan HC, Van Tol HH, Niznik HB.
    Synapse; 1993 Aug 15; 14(4):247-53. PubMed ID: 8248849
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
    Hall H, Högberg T, Halldin C, Bengtsson S, Wedel I.
    Eur J Pharmacol; 1991 Aug 16; 201(1):1-10. PubMed ID: 1686586
    [Abstract] [Full Text] [Related]

  • 9. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
    Hall H, Wedel I.
    Acta Pharmacol Toxicol (Copenh); 1986 May 16; 58(5):368-73. PubMed ID: 2943136
    [Abstract] [Full Text] [Related]

  • 10. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum.
    Terai M, Hidaka K, Nakamura Y.
    Eur J Pharmacol; 1989 Dec 07; 173(2-3):177-82. PubMed ID: 2576228
    [Abstract] [Full Text] [Related]

  • 11. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
    Köhler C, Karlsson-Boethius G.
    J Neural Transm; 1988 Dec 07; 73(2):87-100. PubMed ID: 2974879
    [Abstract] [Full Text] [Related]

  • 12. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P, Guan HC, Niznik HB.
    Synapse; 1989 Dec 07; 3(1):96-7. PubMed ID: 2521961
    [No Abstract] [Full Text] [Related]

  • 13. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390.
    Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P.
    Neuroscience; 1991 Dec 07; 40(3):657-71. PubMed ID: 2062437
    [Abstract] [Full Text] [Related]

  • 14. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
    Florijn WJ, Tarazi FI, Creese I.
    J Pharmacol Exp Ther; 1997 Feb 07; 280(2):561-9. PubMed ID: 9023264
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes.
    Hall H, Wedel I, Halldin C, Kopp J, Farde L.
    J Neurochem; 1990 Dec 07; 55(6):2048-57. PubMed ID: 1977888
    [Abstract] [Full Text] [Related]

  • 16. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand.
    Seeman P, Van Tol HH.
    Eur J Pharmacol; 1995 Oct 15; 291(2):59-66. PubMed ID: 8566176
    [Abstract] [Full Text] [Related]

  • 17. The effect of acute kainic acid treatment on dopamine D2 receptors in rat brain.
    Ridd MJ, Kitchen I, Fosbraey P.
    Neurosci Res; 1998 Mar 15; 30(3):201-11. PubMed ID: 9593330
    [Abstract] [Full Text] [Related]

  • 18. Is clozapine selective for the dopamine D4 receptor?
    Durcan MJ, Rigdon GC, Norman MH, Morgan PF.
    Life Sci; 1995 Mar 15; 57(18):PL275-83. PubMed ID: 7475902
    [Abstract] [Full Text] [Related]

  • 19. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.
    Mohell N, Sällemark M, Rosqvist S, Malmberg A, Högberg T, Jackson DM.
    Eur J Pharmacol; 1993 Jul 06; 238(1):121-5. PubMed ID: 8405075
    [Abstract] [Full Text] [Related]

  • 20. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
    Köhler C, Karlsson-Boethius G.
    J Neural Transm; 1989 Jul 06; 76(1):13-28. PubMed ID: 2523467
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.